MLKL and esophageal cancer: Thus, MLKL has become a prognostic biomarker for patients with early-stage resected PDAC.591 However, high levels of MLKL are tied to poor prognosis in patients with colon and esophageal cancers.596 The mRNA expression level of MLKL in gastric cancer tissues is significantly higher than that in normal tissues.592 The possible reason for this difference is that some cancer cells activate necrosis to modulate the immune system, and the exact mechanism needs to be further investigated.577 In short, MLKL is a potential prognostic biomarker for cancer patients.